0.3850USD-2.36%Mkt Cap: —P/E: —1d ago
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized Bi…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value-1.13M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-10.24M $
Revenue/Share—
Last Price0.3850 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees13
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA0.10
EV/Revenue—
P/S—
P/B1.24
EPS (TTM)-0.35
EPS (Forward)—
52W Range
0.376337% of range0.4000
52W High0.4000 USD
52W Low0.3763 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-241.65%
ROA-84.87%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.74M $
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-9.51M $
Net Debt/EBITDA0.86
Balance Sheet
Debt/Equity4.55
Current Ratio2.77
Quick Ratio2.67
Book Value/Sh0.3070 USD
Cash/Share0.4510 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split0.0625:1
Split DateJun 6, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float21.66M
Insiders4.59%
Institutions6.72%
Technical
SMA 500.6783 (-43.2%)
SMA 2000.8142 (-52.7%)
Beta1.92
S&P 52W Chg18.16%
Avg Vol (30d)4.28K
Avg Vol (10d)792
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—